How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare unfractionated heparin (UFH) and bivalirudin in the performance and subsequent outcomes of Primary percutaneous coronary intervention. This will be a pragmatic trial. Interventional procedures will be performed to reflect current and evolving standards, including predominant radial access. All patients will be treated with routine oral anti-platelet therapy pre-procedure. GP IIb/IIIa inhibitors will be reserved for 'bail out' treatment only.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Liverpool Heart and Chest Hospital NHS Foundation Trust
• Treatments: Bivalirudin; Calcium heparin; Heparin; Hirudins

Criteria

Inclusion Criteria:

• All patients presenting with a suspected myocardial infarction event with PPCI as the proposed index reperfusion strategy will be included in the trial

Exclusion Criteria:

• ≤ 18 years of age

• Known intolerance, hypersensitivity or contraindication to any trial medication

• Active bleeding at presentation

• Artificial ventilation, reduced conscious level or other factors precluding the administration of oral antiplatelet therapy

• Previous enrolment in this trial